KK3A Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
MYQORZO Launch TractionMYQORZO is showing meaningful early commercial adoption, with rapidly rising dispensed patients, expanding prescriber reach, and strong new-to-brand share. Continued prescription growth and broader provider awareness could establish a durable product revenue base as access processes mature.
Positive Aficamten DataPositive pivotal data strengthens aficamten’s potential across the broader hypertrophic cardiomyopathy population and supports the planned nHCM supplemental filing. Successful expansion would deepen Cytokinetics’ cardiovascular franchise and increase the addressable market for its lead medicine.
Strengthened LiquidityThe financing materially improves Cytokinetics’ ability to fund commercialization, regulatory filings, and late-stage clinical programs. A larger liquidity cushion provides operational flexibility while the company works toward product revenue growth and reduces near-term dependence on additional capital.
Bears Say
Heavy Cash BurnSubstantial negative operating and free cash flow means Cytokinetics is consuming significant resources before its commercial base is fully established. Continued investment in launches and trials may require substantial funding, making cash generation and eventual profitability important execution priorities.
Pressured Capital StructureNegative equity combined with high debt indicates a financially pressured capital structure and reliance on external financing. This reduces flexibility during extended development or commercialization periods and can constrain capital allocation even with the recently strengthened cash balance.
Commercial Access FrictionPrescription-to-dispense delays can slow conversion of commercial demand into realized revenue and increase the effort required from the sales and support infrastructure. Persistent access hurdles could temper launch efficiency and postpone the point at which MYQORZO offsets elevated operating costs.
Cytokinetics News
KK3A FAQ
What was Cytokinetics’s price range in the past 12 months?
Currently, no data Available
What is Cytokinetics’s market cap?
Cytokinetics’s market cap is CHF7.26B.
When is Cytokinetics’s upcoming earnings report date?
Cytokinetics’s upcoming earnings report date is Oct 29, 2026 which is in 17 days.
How were Cytokinetics’s earnings last quarter?
Cytokinetics released its earnings results on Aug 06, 2026. The company reported -CHF1.244 earnings per share for the quarter, beating the consensus estimate of -CHF1.35 by CHF0.106.
Is Cytokinetics overvalued?
According to Wall Street analysts Cytokinetics’s price is currently Undervalued.
Does Cytokinetics pay dividends?
Cytokinetics does not currently pay dividends.
What is Cytokinetics’s EPS estimate?
Cytokinetics’s EPS estimate is -1.2.
How many shares outstanding does Cytokinetics have?
Currently, no data Available
What happened to Cytokinetics’s price movement after its last earnings report?
Cytokinetics reported an EPS of -CHF1.244 in its last earnings report, beating expectations of -CHF1.35. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Cytokinetics?
Currently, no hedge funds are holding shares in CH:KK3A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cytokinetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF91.54 (― Upside)
CHF91.54 (― Upside)
Blogger Sentiment
Neutral
CH:KK3A Sentiment 50%
Sector Average 67%
Sector Average 67%
Insider Transactions
Sold Shares
Worth CHF10.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
4.31%
12-Months-Change
Fundamentals
Return on Equity
163.98%
Trailing 12-Months
Asset Growth
57.02%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cytokinetics
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
KK3A Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial operational and clinical progress: strong early commercial momentum for MYQORZO (rapidly growing prescriptions, rising awareness, >700 prescribers and >1,500 dispensed patients), pivotal ACACIA-HCM positive results with planned sNDA submission, successful European regulatory steps and a $760M financing that boosted cash to ~$1.7B. These strategic and scientific achievements were balanced against near-term financial headwinds including a YOY revenue decline driven by absence of milestone revenue, a wider GAAP net loss ($198.8M), sharply higher SG&A tied to launch costs and upwardly revised 2026 expense guidance. Overall, the operational wins, pivotal data and strong cash position indicate a constructive outlook for growth and future approvals, though investors should expect continued elevated spending as the company scales commercialization and pursues regulatory filings.View all CH:KK3A earnings summariesKK3A Stock 12 Month Forecast
Average Price Target
―Sarepta Therapeutics
―
PTC Therapeutics
―
Scholar Rock Holding
―
Dyne Therapeutics
―
Edgewise Therapeutics
―